Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.

Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, Li Y, Boppana M, de Leon MJ.

Neurology. 2005 Jun 14;64(11):1860-7.

PMID:
15955934
2.

Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, Kemppainen N, Någren K, Kim BC, Tsui W, de Leon MJ.

Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2169-81. doi: 10.1007/s00259-008-0833-y. Epub 2008 Jun 20.

3.

Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET.

Mosconi L, De Santi S, Li Y, Li J, Zhan J, Tsui WH, Boppana M, Pupi A, de Leon MJ.

Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):210-21. Epub 2005 Nov 26.

PMID:
16311757
4.

Hippocampal hypometabolism predicts cognitive decline from normal aging.

Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H, de Leon MJ.

Neurobiol Aging. 2008 May;29(5):676-92. Epub 2007 Jan 11.

5.

Hippocampal formation glucose metabolism and volume losses in MCI and AD.

De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, Tsui WH, Kandil E, Boppana M, Daisley K, Wang GJ, Schlyer D, Fowler J.

Neurobiol Aging. 2001 Jul-Aug;22(4):529-39.

PMID:
11445252
6.

Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.

Grimmer T, Wutz C, Alexopoulos P, Drzezga A, Förster S, Förstl H, Goldhardt O, Ortner M, Sorg C, Kurz A.

J Nucl Med. 2016 Feb;57(2):204-7. doi: 10.2967/jnumed.115.163717. Epub 2015 Nov 19.

7.

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC.

Brain. 2008 Mar;131(Pt 3):665-80. doi: 10.1093/brain/awm336. Epub 2008 Feb 7.

8.

FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.

Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, Pirraglia E, De Santi S, Reisberg B, Wisniewski T, de Leon MJ.

Eur J Nucl Med Mol Imaging. 2009 May;36(5):811-22. doi: 10.1007/s00259-008-1039-z. Epub 2009 Jan 14.

9.
10.

Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.

Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ.

J Nucl Med. 2008 Mar;49(3):390-8. doi: 10.2967/jnumed.107.045385. Epub 2008 Feb 20.

11.

Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.

Furukawa K, Okamura N, Tashiro M, Waragai M, Furumoto S, Iwata R, Yanai K, Kudo Y, Arai H.

J Neurol. 2010 May;257(5):721-7. doi: 10.1007/s00415-009-5396-8. Epub 2009 Nov 28.

PMID:
19946781
12.

Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.

Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A.

Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1104-13. Epub 2003 May 23.

PMID:
12764551
13.

Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment.

Albin RL, Koeppe RA, Burke JF, Giordani B, Kilbourn MR, Gilman S, Frey KA.

Arch Neurol. 2010 Apr;67(4):440-6. doi: 10.1001/archneurol.2010.34.

14.

Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.

Lange C, Suppa P, Frings L, Brenner W, Spies L, Buchert R.

J Alzheimers Dis. 2016;49(4):945-59. doi: 10.3233/JAD-150814.

PMID:
26577523
15.

MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.

Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A.

Neurology. 2004 Dec 28;63(12):2332-40.

PMID:
15623696
16.

Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease.

Kawachi T, Ishii K, Sakamoto S, Sasaki M, Mori T, Yamashita F, Matsuda H, Mori E.

Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):801-9. Epub 2006 Mar 21.

PMID:
16550383
17.

Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.

Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G.

J Nutr Health Aging. 2008 Jan;12(1):61S-5S.

PMID:
18165848
18.

(18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease.

Mosconi L, Tsui WH, Pupi A, De Santi S, Drzezga A, Minoshima S, de Leon MJ.

J Nucl Med. 2007 Jul;48(7):1129-34. Epub 2007 Jun 15.

19.

Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease.

Karow DS, McEvoy LK, Fennema-Notestine C, Hagler DJ Jr, Jennings RG, Brewer JB, Hoh CK, Dale AM; Alzheimer's Disease Neuroimaging Initiative..

Radiology. 2010 Sep;256(3):932-42. doi: 10.1148/radiol.10091402.

20.

Generative FDG-PET and MRI model of aging and disease progression in Alzheimer's disease.

Dukart J, Kherif F, Mueller K, Adaszewski S, Schroeter ML, Frackowiak RS, Draganski B; Alzheimer's Disease Neuroimaging Initiative..

PLoS Comput Biol. 2013 Apr;9(4):e1002987. doi: 10.1371/journal.pcbi.1002987. Epub 2013 Apr 4.

Supplemental Content

Support Center